About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE (Therapy)
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Media Library
Philogen in the news
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE (Therapy)
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Philogen in the news
Media Library
Work with us
Careers
Partnering
News & Events
2022
,
Investors
,
Press Releases
L’Assemblea degli Azionisti ha approvato il bilancio di esercizio 2021 e la politica di remunerazione, ha nominato il nuovo Consiglio di Amministrazione e il relativo presidente per il triennio 2022-2024
Apr 27, 2022
More details
Last News & Events
Jul
2026
27
Nidlegy™ Marketing Authorization Application Resubmitted to EMA
May
2026
21
Deposito del Verbale dell’Assemblea degli Azionisti
1
2
3
…
146
Next »